SAN DIEGO (Legal Newsline) — The manufacturers of Metformin, the fourth-most prescribed medicine in the U.S. used to treat diabetes, are facing a class action lawsuit alleging they falsely touted the drug as safe when it contained a carcinogen.
MSP Recover Claims, Series LLC, on behalf of similarly situated health care insurers, filed a complaint April 3 in the U.S. District Court for the Southern District of California against Aurobindo Pharm LTD, Aurolife Pharma, LLC, Heritage Pharmaceuticals LLC and others alleging fraud and other claims.
The plaintiffs allege in their complaint that the defendants knowingly concealed that their prescription type 2 diabetes drug Metformin contains N-nitrosodimethylamine (NDMA), a carcinogen and liver-damaging contaminant. They claim a March 2020 test revealed Metformin contained 8.6 times the amount of NDMA than the FDA's interim daily limit.
The plaintiffs seek monetary relief, trial by jury and all other just relief. They a represented by Jorge Mestre, Andrés Rivero, Alan Rolnick, Charles Whorton and David Daponte of Rivero Mestre LLP in Miami.
U.S. District Court for the Southern District of California case number 1:20-CV-21456-UU.